Evaxion A (EVAX) Revenue (2024 - 2025)
Evaxion A's (EVAX) quarterly Revenue came in at $7.5 million in Q3 2025, up 148.33% YoY from $3.0 million in Q3 2024, and up 20148.65% on a QoQ basis from $37000.0 in Q2 2025.
Evaxion A (EVAX) Revenue (2024 - 2025) Analysis & Trends
Evaxion A (EVAX) has 2 years of Revenue data on file, last reported at $7.5 million in Q3 2025.
- Quarterly Revenue rose 148.33% year-over-year to $7.5 million in Q3 2025, while the trailing twelve-month figure through Mar 2026 was $7.5 million (up 128.64% YoY) and the FY2025 annual result came in at $7.5 million, up 125.12% from the prior year.
- Revenue advanced to $7.5 million in Q3 2025, from $37000.0 in the prior quarter.
- In the past five years, Revenue ranged from a high of $7.5 million in Q3 2025 to a low of $37000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.29 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 425.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 674.14 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.06 Bn |
| 10 | Evaxion A | 26.86 Mn | 26.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 7.49 Mn |
| Jun 30, 2025 | 37,000.00 |
| Dec 31, 2024 | 122,000.00 |
| Sep 30, 2024 | 3.02 Mn |
| Jun 30, 2024 | 154,000.00 |
| Mar 31, 2024 | 51,000.00 |